Questions around this news
What interim results did LIXTE report from its ovarian cancer trial?
The release reports interim data from 20 evaluable patients in a trial combining LB-100 with dostarlimab. The reported disease control rate was 40%, with what the company described as encouraging survival trends and an acceptable safety profile. The company said the findings support continued enrollment of an expanded cohort.
What does disease control rate mean in a cancer trial?
Disease control rate is the proportion of patients whose cancer meets a study’s criteria for being controlled during a specified assessment period. Depending on the trial’s definitions, this can include patients whose tumors shrink or remain stable, rather than only those whose tumors shrink. The exact criteria and timing can vary between studies.
Why is LB-100 being tested with dostarlimab?
The release says the trial is investigating whether the combination could enhance the response to immunotherapy in ovarian clear cell carcinoma. It describes LB-100 as a compound being evaluated alongside dostarlimab and says the preliminary results support continued enrollment. It does not provide a detailed explanation of the biological rationale for combining the two drugs.
What is ovarian clear cell carcinoma?
Ovarian clear cell carcinoma is a less common subtype of epithelial ovarian cancer, named for the appearance of its tumor cells under a microscope. Its features and response to treatment can differ from those of other ovarian cancer subtypes, so research may examine it separately in clinical trials.
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company advancing cancer treatments, announced preliminary results from a clinical trial evaluating its proprietary compound LB-100 in combination with dostarlimab at the 2026 Society of Gynecologic Oncology conference in San Juan, Puerto Rico. Interim data from 20 evaluable patients showed a 40% disease control rate and encouraging survival trends with an acceptable safety profile, supporting continued enrollment of an expanded cohort as the company investigates the combination’s potential to enhance immunotherapy response in ovarian clear cell carcinoma.
To view the full press release, visit https://ibn.fm/alcex
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that LB-100, its lead compound and first-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information can be found at .
Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at .
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- LIXTE Biotechnology Holdings
- Ticker
- NASDAQ: LIXT
- Location
- San Juan, Puerto Rico
Key figures
- Evaluable patients in interim data
- 20
- Disease control rate
- 40%
Products and programs
Earlier from LIXTE Biotechnology Holdings, Inc.
- Lixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships
- LIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year
- LIXTE Biotechnology (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes
- LIXTE Biotechnology (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials
- Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership
